drugset / Trial / NCT02884219

Early Treatment Versus Expectative Management of PDA in Preterm Infants

NCT02884219

RandomizedParallel-groupOpen-labelTreatment

Summary

Much controversy exists about the optimal management of a patent ductus arteriosus (PDA) in preterm infants, especially in those born at a gestational age \<28 weeks and/or a birth weight ≦1000 grams due to a lack of evidence for or against different approaches. A PDA has been associated with serious complications. However, a common finding is that medical and/or surgical treatment of a PDA seems not to reduce the risk of mortality or major morbidity. This might be related to the fact that a substantial portion of preterm infants are treated unnecessarily, because the ductus arteriosus (DA) might have closed spontaneously without any specific intervention. An expectative approach is gaining interest, although convincing evidence is still missing. The objective of this study is to investigate whether in preterm infants \<28 weeks' gestation with a PDA an expectative management is not inferior to early treatment with regard to the composite of mortality and/or necrotizing enterocolitis (NEC) and/or bronchopulmonary dysplasia (BPD) at a postmenstrual age of 36 weeks.

Timeline

Start
2016-12-23
Primary completion
2022-03-15
Completion
2022-03-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule Intravenous
Comparator Indomethacin Small molecule